Bristol Myers Squibb

New cell therapy facility at Leiden Bio Science Park
American pharmaceutical company Bristol Myers Squibb (BMS) will be building a new cell therapy facility in the Oegstgeest part of the Leiden Bio Science Park. The company will manufacture and develop cell therapy for, amongst others, leukaemia patients.

Information

BMS is one of the largest biopharmaceutical companies in the world. The new cell therapy facility at the Leiden Bio Science Park (LBSP) will be its fifth such facility in the world and its first European one. Its aim is to bring cell therapy closer to European patients. The facility will have the latest technology and production equipment for cell therapy development, thus enabling the company to increase its capacity for treating cancer patients.

BMS is one of the largest biopharmaceutical companies in the world. The new cell therapy facility at the Leiden Bio Science Park (LBSP) will be its fifth such facility in the world and its first European one. Its aim is to bring cell therapy closer to European patients. The facility will have the latest technology and production equipment for cell therapy development, thus enabling the company to increase its capacity for treating cancer patients.

Location

Planned
  • Run time
    2021-2024
  • Type
    Life, Science & Health
  • Landowner
    Gemeente Leiden Universiteit Leiden
  • Surface area
    19.000 m2
  • Credits Architect: KuiperCompagnons
  • Roadworks Roadworks may affect traffic in the local area. For more information, please press the red button ‘All roadworks’.